Gilead sciences and arcus biosciences expand partnership to include research programs in inflammation

Foster city, calif., & hayward, calif.--(business wire)--gilead sciences, inc. (nasdaq:gild) and arcus biosciences, inc. (nyse:rcus) today announced that the companies have expanded the previously announced research collaboration focused on oncology to include therapies for the treatment of inflammatory diseases. the expanded collaboration builds upon gilead's growing presence in inflammatory disease and serves as a step towards broadening arcus' capabilities and portfolio beyond oncology and i.
RCUS Ratings Summary
RCUS Quant Ranking